RT Journal Article
SR Electronic
T1 Post-COVID syndrome is associated with capillary alterations, macrophage infiltration and distinct transcriptomic signatures in skeletal muscles
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.15.23285584
DO 10.1101/2023.02.15.23285584
A1 Aschman, Tom
A1 Wyler, Emanuel
A1 Baum, Oliver
A1 Hentschel, Andreas
A1 Legler, Franziska
A1 Preusse, Corinna
A1 Meyer-Arndt, Lil
A1 Büttnerova, Ivana
A1 Förster, Alexandra
A1 Cengiz, Derya
A1 Teixeira Alves, Luiz Gustavo
A1 Schneider, Julia
A1 Kedor, Claudia
A1 Rust, Rebecca
A1 Bellmann-Strobl, Judith
A1 Aminaa, Sanchin
A1 Vajkoczy, Peter
A1 Goebel, Hans-Hilmar
A1 Landthaler, Markus
A1 Corman, Victor
A1 Roos, Andreas
A1 Heppner, Frank L.
A1 Radbruch, Helena
A1 Paul, Friedemann
A1 Scheibenbogen, Carmen
A1 Stenzel, Werner
A1 Dengler, Nora F.
YR 2023
UL http://medrxiv.org/content/early/2023/02/16/2023.02.15.23285584.abstract
AB The SARS-CoV-2 pandemic not only resulted in millions of acute infections worldwide, but also caused innumerable cases of post-infectious syndromes, colloquially referred to as “long COVID”. Due to the heterogeneous nature of symptoms and scarcity of available tissue samples, little is known about the underlying mechanisms. We present an in-depth analysis of skeletal muscle biopsies obtained from eleven patients suffering from enduring fatigue and post-exertional malaise after an infection with SARS-CoV-2. Compared to two independent historical control cohorts, patients with post-COVID exertion intolerance had fewer capillaries, thicker capillary basement membranes and increased numbers of CD169+ macrophages. SARS-CoV-2 RNA could not be detected in the muscle tissues, but transcriptomic analysis revealed distinct gene signatures compared to the two control cohorts, indicating immune dysregulations and altered metabolic pathways. We hypothesize that the initial viral infection may have caused immune-mediated structural changes of the microvasculature, potentially explaining the exercise-dependent fatigue and muscle pain.Competing Interest StatementND accepted speaker honoraria of Integra LifeSciences and serves as advisor for Alexion Pharmaceuticals. Funding StatementHelmholtz Association Initiative and Networking Fund grant KA1-Co-02 COVIPA (EW, LGTA, ML) European Commission grant Go Safe Horizon 2020, 870144 (ND) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Charite - Universitaetsmedizin Berlin (EA2/066/20 and EA2/163/17) in accordance with the 1964 Declaration of Helsinki and its later amendments.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.